<DOC>
	<DOCNO>NCT00001203</DOCNO>
	<brief_summary>When patient receive repeat blood transfusion level iron patient blood rise . When iron process body protein know hemosiderin begin collect organ . If much hemosiderin collect organs begin malfunction . This condition call transfusional hemochromatosis . An organ particular importance transfusional hemochromatosis heart . Patients born disease require blood transfusion birth begin develop heart problem teen . These patient typically live 17 year . Adults require transfusion begin experience heart problem 100-200 unit back red blood cell . Deferoxamine ( Desferal ) drug bind iron allows excrete body . It effective way remove iron patient overload iron multiple transfusion . Previous study lead researcher believe deferoxamine , give injection skin ( subcutaneous ) , delay prevent heart complication . Researchers plan continue study patient receive deferoxamine treatment prevention heart complication associate repeat blood transfusion . In study researcher attempt ; 1 . To determine deferoxamine , give regularly , indefinitely prevent heart , liver , endocrine complication associate transfusional hemochromatosis 2 . To determine whether heart disease cause transfusional hemochromatosis reverse intensive treatment deferoxamine .</brief_summary>
	<brief_title>Deferoxamine Treatment Hemochromatosis</brief_title>
	<detailed_description>The purpose protocol two-fold : 1 ) determine whether deferoxamine , give subcutaneously regular basis , indefinitely prevent cardiac , endocrine hepatic complication transfusional hemochromatosis ; 2 ) determine whether cardiac disease reverse intensive intravenous treatment patient already objective evidence cardiac dysfunction . The clinical manifestation course patient require regular blood transfusion well establish . Those congenital anemias require transfusion birth develop cardiac disease teen mean survival 17 year . Adults acquire anemias begin exhibit cardiac manifestation iron deposition 100-200 unit pack red cell . Deferoxamine , give subcutaneous route , show reduce substantially total iron burden thalassemic patient . Our result indicate cardiac complication delay prevent . We plan continue follow cohort patient optimal medical management determine chelation alters disease outcome . Patients heavy iron burden already manifest cardiac disease chelate intensely determine whether reduce iron burden associate reversal cardiac complication .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Hemochromatosis</mesh_term>
	<mesh_term>Deferoxamine</mesh_term>
	<criteria>INCLUSION CRITERIA Patients study protocol risk evidence significant excess tissue iron . Most patient regular blood transfusion secondary either congenital acquire anemia . The majority patient homozygous beta thalassemia . Patients sickle cell anemia include absolute indication regular blood transfusion ( e.g. , history stroke ) . Twenty thirty adult acquire anemia good longterm prognosis accept study chelation initiate early transfusion history ( less 3050 unit ) . EXCLUSION CRITERIA Such patient exclude study diabetes cardiac disease due another cause ( coronary artery valvular heart disease ) .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 9, 2015</verification_date>
	<keyword>Desferal</keyword>
	<keyword>Thalassemia</keyword>
	<keyword>Liver Iron Concentration</keyword>
	<keyword>Endocrine Evaluation</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Cardiac Disease</keyword>
	<keyword>Acquired Anemia</keyword>
</DOC>